LAVA Medtech Acquisition Performance
LVACDelisted Stock | USD 10.44 0.00 0.00% |
The firm secures a Beta (Market Risk) of -0.0268, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning LAVA Medtech are expected to decrease at a much lower rate. During the bear market, LAVA Medtech is likely to outperform the market. LAVA Medtech Acquisition currently secures a risk of 0.0%. Please verify LAVA Medtech Acquisition expected short fall, and the relationship between the potential upside and rate of daily change , to decide if LAVA Medtech Acquisition will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days LAVA Medtech Acquisition has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, LAVA Medtech is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Begin Period Cash Flow | 1.5 M |
LAVA |
LAVA Medtech Relative Risk vs. Return Landscape
If you would invest 1,044 in LAVA Medtech Acquisition on September 1, 2024 and sell it today you would earn a total of 0.00 from holding LAVA Medtech Acquisition or generate 0.0% return on investment over 90 days. LAVA Medtech Acquisition is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than LAVA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
LAVA Medtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LAVA Medtech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LAVA Medtech Acquisition, and traders can use it to determine the average amount a LAVA Medtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
LVAC |
Based on monthly moving average LAVA Medtech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LAVA Medtech by adding LAVA Medtech to a well-diversified portfolio.
LAVA Medtech Fundamentals Growth
LAVA Stock prices reflect investors' perceptions of the future prospects and financial health of LAVA Medtech, and LAVA Medtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LAVA Stock performance.
Return On Asset | -0.0081 | |||
Current Valuation | 144.92 M | |||
Shares Outstanding | 11.5 M | |||
Price To Book | 1.27 X | |||
EBITDA | (6.22 M) | |||
Cash And Equivalents | 1.15 M | |||
Cash Per Share | 0.08 X | |||
Total Debt | 92.81 K | |||
Debt To Equity | 4.92 % | |||
Book Value Per Share | (0.21) X | |||
Cash Flow From Operations | (658.82 K) | |||
Earnings Per Share | 0.31 X | |||
Total Asset | 120.67 M | |||
Retained Earnings | (3.01 M) | |||
About LAVA Medtech Performance
By analyzing LAVA Medtech's fundamental ratios, stakeholders can gain valuable insights into LAVA Medtech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if LAVA Medtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LAVA Medtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
LAVA Medtech Acquisition Corp. does not have significant operations. LAVA Medtech Acquisition Corp. is a subsidiary of LAVA Medtech Sponsor LP. Lava Medtech is traded on NASDAQ Exchange in the United States.Things to note about LAVA Medtech Acquisition performance evaluation
Checking the ongoing alerts about LAVA Medtech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LAVA Medtech Acquisition help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.LAVA Medtech is not yet fully synchronised with the market data | |
LAVA Medtech has a very high chance of going through financial distress in the upcoming years | |
LAVA Medtech Acquisition currently holds about 1.15 M in cash with (658.82 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
Over 92.0% of the company shares are owned by institutional investors |
- Analyzing LAVA Medtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LAVA Medtech's stock is overvalued or undervalued compared to its peers.
- Examining LAVA Medtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LAVA Medtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LAVA Medtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LAVA Medtech's stock. These opinions can provide insight into LAVA Medtech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in LAVA Stock
If you are still planning to invest in LAVA Medtech Acquisition check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LAVA Medtech's history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |